B of A Securities Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $30

Benzinga Newsdesk www.benzinga.com Positive 78.0%

Neg 0% Neu 0% Pos 78%

B of A Securities analyst Tazeen Ahmad maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $29 to $30.